Law360, New York (January 8, 2014, 8:12 PM EST) -- GlaxoSmithKline LLC on Monday blasted a bid to have the Third Circuit decide whether the company could send a suit alleging antidepressant drug Paxil caused birth defects from state to federal court more than a year after the suit began.
GSK challenged the plaintiffs' Dec. 23 petition for permission to appeal the company's removal of the case to federal court following a landmark Third Circuit ruling in June keeping a separate suit over GSK's morning-sickness drug thalidomide in federal court, saying there were no exceptional circumstances to warrant an appellate review and that an immediate appeal would not materially advance the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!